| Year |
Citation |
Score |
| 2023 |
Khalsa JK, Cha J, Utro F, Naeem A, Murali I, Kuang Y, Vasquez KA, Li L, Tyekucheva S, Fernandes SM, Veronese L, Guieze R, Kandathilparambil Sasi B, Wang Z, Machado JH, ... ... Brown JR, et al. Genetic events associated with venetoclax resistance in CLL identified by whole exome sequencing of patient samples. Blood. PMID 37146250 DOI: 10.1182/blood.2022016600 |
0.398 |
|
| 2023 |
Gadi D, Martindale SP, Chiu PY, Khalsa J, Chen PH, Fernandes SM, Wang Z, Tyekucheva S, Machado JH, Fisher DC, Armand P, Davids MS, Rodig S, Sherry B, Brown JR. Circulating Th17 T cells at treatment onset predict autoimmune toxicity of PI3Kδ inhibitors. Blood Cancer Journal. 13: 22. PMID 36732326 DOI: 10.1038/s41408-023-00788-9 |
0.535 |
|
| 2023 |
Arribas AJ, Napoli S, Cascione L, Barnabei L, Sartori G, Cannas E, Gaudio E, Tarantelli C, Mensah AA, Spriano F, Zucchetto A, Rossi FM, Rinaldi A, de Moura MC, Jovic S, ... ... Brown JR, et al. ERBB4-mediated signaling is a mediator of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasms. Biorxiv : the Preprint Server For Biology. PMID 36711490 DOI: 10.1101/2023.01.01.522017 |
0.393 |
|
| 2022 |
Brown JR, Eichhorst B, Hillmen P, Jurczak W, Kaźmierczak M, Lamanna N, O'Brien SM, Tam CS, Qiu L, Zhou K, Simkovic M, Mayer J, Gillespie-Twardy A, Ferrajoli A, Ganly PS, et al. Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia. The New England Journal of Medicine. PMID 36511784 DOI: 10.1056/NEJMoa2211582 |
0.302 |
|
| 2022 |
Ahn IE, Brown JR. Selecting initial therapy in CLL. Hematology. American Society of Hematology. Education Program. 2022: 323-328. PMID 36485152 DOI: 10.1182/hematology.2022000343 |
0.387 |
|
| 2022 |
Naeem A, Utro F, Wang Q, Cha J, Vihinen M, Martindale SP, Zhou Y, Ren Y, Tyekucheva S, Kim AS, Fernandes SM, Saksena G, Rhrissorrakrai K, Levovitz C, Danysh BP, ... ... Brown JR, et al. Pirtobrutinib Targets BTK C481S in Ibrutinib-Resistant CLL but Second-Site BTK Mutations Lead to Resistance. Blood Advances. PMID 36287227 DOI: 10.1182/bloodadvances.2022008447 |
0.538 |
|
| 2022 |
Yin Y, Athanasiadis P, Karlsen L, Urban A, Xu H, Murali I, Fernandes SM, Arribas AJ, Hilli AK, Taskén K, Bertoni F, Mato AR, Normant E, Brown JR, Tjønnfjord GE, et al. Functional testing to characterize and stratify PI3K inhibitor responses in chronic lymphocytic leukemia. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 35998013 DOI: 10.1158/1078-0432.CCR-22-1221 |
0.334 |
|
| 2022 |
Kaufman M, Yan XJ, Li W, Ghia EM, Langerak AW, Rassenti LZ, Belessi C, Kay NE, Davi F, Byrd JC, Pospisilova S, Brown JR, Catherwood M, Davis Z, Oscier D, et al. Impact of the Types and Relative Quantities of IGHV Gene Mutations in Predicting Prognosis of Patients With Chronic Lymphocytic Leukemia. Frontiers in Oncology. 12: 897280. PMID 35903706 DOI: 10.3389/fonc.2022.897280 |
0.323 |
|
| 2022 |
Tam CS, Brown JR, Kahl BS, Ghia P, Giannopoulos K, Jurczak W, Šimkovič M, Shadman M, Österborg A, Laurenti L, Walker P, Opat S, Chan H, Ciepluch H, Greil R, et al. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. The Lancet. Oncology. PMID 35810754 DOI: 10.1016/S1470-2045(22)00293-5 |
0.35 |
|
| 2022 |
Wierda WG, Brown J, Abramson JS, Awan F, Bilgrami SF, Bociek G, Brander D, Chanan-Khan AA, Coutre SE, Davis RS, Eradat H, Fletcher CD, Gaballa S, Ghobadi A, Hamid MS, et al. NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022. Journal of the National Comprehensive Cancer Network : Jnccn. 20: 622-634. PMID 35714675 DOI: 10.6004/jnccn.2022.0031 |
0.348 |
|
| 2022 |
Mamidi MK, Mahmud H, Maiti GP, Mendez MT, Fernandes SM, Vesely SK, Holter-Chakrabarty J, Brown JR, Ghosh AK. Idelalisib activates AKT via increased recruitment of PI3Kδ/PI3Kβ to BCR signalosome while reducing PDK1 in post-therapy CLL cells. Leukemia. PMID 35568768 DOI: 10.1038/s41375-022-01595-0 |
0.429 |
|
| 2022 |
Arribas AJ, Napoli S, Cascione L, Sartori G, Barnabei L, Gaudio E, Tarantelli C, Mensah AA, Spriano F, Zucchetto A, Rossi FM, Rinaldi A, De Moura MC, Jovic S, Bordone-Pittau R, ... ... Brown JR, et al. Resistance to PI3κδ inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axis. Haematologica. PMID 35484662 DOI: 10.3324/haematol.2021.279957 |
0.329 |
|
| 2022 |
Gadi D, Griffith A, Wang Z, Tyekucheva S, Rai V, Fernandes SM, Machado JH, Munugalavadla V, Lederer J, Brown JR. Idelalisib reduces regulatory T cells and activates T helper 17 cell differentiation in relapsed refractory patients with chronic lymphocytic leukaemia. British Journal of Haematology. PMID 35170759 DOI: 10.1111/bjh.18053 |
0.44 |
|
| 2021 |
Melvold K, Giliberto M, Karlsen L, Ayuda-Durán P, Hanes R, Holien T, Enserink J, Brown JR, Tjønnfjord GE, Taskén K, Skånland SS. Mcl-1 and Bcl-xL levels predict responsiveness to dual MEK/Bcl-2 inhibition in B-cell malignancies. Molecular Oncology. PMID 34861096 DOI: 10.1002/1878-0261.13153 |
0.384 |
|
| 2021 |
O'Brien SM, Brown JR, Byrd JC, Furman RR, Ghia P, Sharman JP, Wierda WG. Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice. Frontiers in Oncology. 11: 720704. PMID 34858810 DOI: 10.3389/fonc.2021.720704 |
0.353 |
|
| 2021 |
Mato AR, Davids MS, Sharman J, Roeker LE, Kay N, Kater AP, Rogers K, Thompson MC, Rhodes J, Goy A, Skarbnik A, Schuster SJ, Tam CS, Eyre TA, O'Brien S, ... ... Brown JR, et al. Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: "What's Past is Prologue" (Shakespeare). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 34789482 DOI: 10.1158/1078-0432.CCR-21-1237 |
0.336 |
|
| 2021 |
Gadi D, Griffith A, Tyekucheva S, Wang Z, Rai V, Vartanov A, Thrash E, Fernandes SM, Lehmberg TZ, Lee B, Martindale SP, Machado JH, Odejide O, Armand P, Fisher DC, ... ... Brown JR, et al. A T cell inflammatory phenotype is associated with autoimmune toxicity of the PI3K inhibitor duvelisib in chronic lymphocytic leukemia. Leukemia. PMID 34743191 DOI: 10.1038/s41375-021-01441-9 |
0.452 |
|
| 2021 |
Biran A, Yin S, Kretzmer H, Ten Hacken E, Parvin S, Lucas F, Uduman M, Gutierrez C, Dangle N, Billington L, Regis FF, Rassenti LZ, Mohammad A, Hoffmann GB, Stevenson K, ... ... Brown JR, et al. Activation of Notch and Myc signaling via B cell-restricted depletion of Dnmt3a generates a consistent murine model of chronic lymphocytic leukemia. Cancer Research. PMID 34686499 DOI: 10.1158/0008-5472.CAN-21-1273 |
0.308 |
|
| 2021 |
Ahn IE, Brown JR. Targeting Bruton's Tyrosine Kinase in CLL. Frontiers in Immunology. 12: 687458. PMID 34248972 DOI: 10.3389/fimmu.2021.687458 |
0.379 |
|
| 2021 |
Lampson BL, Brown JR. The Evolving Use of Phosphatidylinositol 3-Kinase Inhibitors for the Treatment of Chronic Lymphocytic Leukemia. Hematology/Oncology Clinics of North America. 35: 807-826. PMID 34174987 DOI: 10.1016/j.hoc.2021.03.009 |
0.365 |
|
| 2021 |
Furman RR, Byrd JC, Owen RG, O'Brien SM, Brown JR, Hillmen P, Stephens DM, Chernyukhin N, Lezhava T, Hamdy AM, Izumi R, Patel P, Baek M, Christian B, Dyer MJS, et al. Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies. Leukemia. PMID 33907299 DOI: 10.1038/s41375-021-01252-y |
0.325 |
|
| 2021 |
Lee JH, Shao S, Kim M, Fernandes SM, Brown JR, Kam LC. Multi-Factor Clustering Incorporating Cell Motility Predicts T Cell Expansion Potential. Frontiers in Cell and Developmental Biology. 9: 648925. PMID 33898440 DOI: 10.3389/fcell.2021.648925 |
0.342 |
|
| 2021 |
Murali I, Kasar S, Naeem A, Tyekucheva S, Khalsa JK, Thrash EM, Itchaki G, Livitz D, Leshchiner I, Dong S, Fernandes SM, Getz G, Johnson A, Brown JR. Activation of the MAPK pathway mediates resistance to PI3K inhibitors in chronic lymphocytic leukemia (cll). Blood. PMID 33684943 DOI: 10.1182/blood.2020006765 |
0.433 |
|
| 2021 |
Mato AR, Shah NN, Jurczak W, Cheah CY, Pagel JM, Woyach JA, Fakhri B, Eyre TA, Lamanna N, Patel MR, Alencar A, Lech-Maranda E, Wierda WG, Coombs CC, Gerson JN, ... ... Brown JR, et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet (London, England). 397: 892-901. PMID 33676628 DOI: 10.1016/S0140-6736(21)00224-5 |
0.353 |
|
| 2020 |
Brown JR, Walker SR, Heppler LN, Tyekucheva S, Nelson EA, Klitgaard J, Nicolais M, Kroll Y, Xiang M, Yeh JE, Chaudhury M, Giaccone ZT, Fernandes SM, Jacobsen ED, Fisher DC, et al. Targeting Constitutively Active STAT3 in Chronic Lymphocytic Leukemia: A Clinical Trial of the STAT3 Inhibitor Pyrimethamine with Pharmacodynamic Analyses. American Journal of Hematology. PMID 33373063 DOI: 10.1002/ajh.26084 |
0.302 |
|
| 2020 |
Choi IK, Wang Z, Ke Q, Hong M, Paul DW, Fernandes SM, Hu Z, Stevens J, Guleria I, Kim HJ, Cantor H, Wucherpfennig KW, Brown JR, Ritz J, Zhang B. Mechanism of EBV inducing anti-tumour immunity and its therapeutic use. Nature. PMID 33361812 DOI: 10.1038/s41586-020-03075-w |
0.334 |
|
| 2020 |
Bachireddy P, Ennis C, Nguyen VN, Gohil SH, Clement K, Shukla SA, Forman J, Barkas N, Freeman S, Bavli N, Elagina L, Leshchiner I, Mohammad AW, Mathewson ND, Keskin DB, ... ... Brown JR, et al. Distinct evolutionary paths in chronic lymphocytic leukemia during resistance to the graft-versus-leukemia effect. Science Translational Medicine. 12. PMID 32938797 DOI: 10.1126/Scitranslmed.Abb7661 |
0.343 |
|
| 2020 |
Kim HT, Shaughnessy CJ, Rai SC, Reynolds C, Ho VT, Cutler C, Koreth J, Gooptu M, Romee R, Nikiforow S, Armand P, Alyea EP, Antin JH, Wu CJ, Soiffer RJ, ... ... Brown JR, et al. Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia. Blood Advances. 4: 4113-4123. PMID 32882002 DOI: 10.1182/Bloodadvances.2020002184 |
0.31 |
|
| 2020 |
Haselager MV, Kielbassa K, Ter Burg J, Bax DJC, Fernandes SM, Borst J, Tam C, Forconi F, Chiodin G, Brown JR, Dubois J, Kater AP, Eldering E. Changes in Bcl-2 members in response to ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL. Blood. PMID 32603412 DOI: 10.1182/blood.2019004326 |
0.327 |
|
| 2020 |
Ryan CE, Cheng MP, Issa NC, Brown JR, Davids MS. Pneumocystis jirovecii pneumonia and institutional prophylaxis practices in CLL patients treated with BTK inhibitors. Blood Advances. 4: 1458-1463. PMID 32282880 DOI: 10.1182/bloodadvances.2020001678 |
0.315 |
|
| 2020 |
Hillmen P, Brown JR, Eichhorst BF, Lamanna N, O'Brien SM, Qiu L, Salmi T, Hilger J, Wu K, Cohen A, Huang J, Tam CS. ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. Future Oncology (London, England). PMID 32207333 DOI: 10.2217/fon-2019-0844 |
0.378 |
|
| 2020 |
Wierda WG, Byrd JC, Abramson JS, Bilgrami SF, Bociek G, Brander D, Brown J, Chanan-Khan AA, Chavez JC, Coutre SE, Davis RS, Fletcher CD, Hill B, Kahl BS, Kamdar M, et al. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : Jnccn. 18: 185-217. PMID 32023533 DOI: 10.6004/Jnccn.2020.0006 |
0.338 |
|
| 2019 |
Byrd JC, Wierda WG, Schuh A, Devereux S, Chaves JM, Brown JR, Hillmen P, Martin P, Awan FT, Stephens DM, Ghia P, Barrientos J, Pagel JM, Woyach JA, Burke K, et al. Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results. Blood. PMID 31876911 DOI: 10.1182/blood.2018884940 |
0.343 |
|
| 2019 |
Brown JR. Phosphatidylinositol 3 Kinase δ Inhibitors: Present and Future. Cancer Journal (Sudbury, Mass.). 25: 394-400. PMID 31764120 DOI: 10.1097/PPO.0000000000000414 |
0.362 |
|
| 2019 |
Guièze R, Liu VM, Rosebrock D, Jourdain AA, Hernández-Sánchez M, Martinez Zurita A, Sun J, Ten Hacken E, Baranowski K, Thompson PA, Heo JM, Cartun Z, Aygün O, Iorgulescu JB, Zhang W, ... ... Brown JR, et al. Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies. Cancer Cell. PMID 31543463 DOI: 10.1016/J.Ccell.2019.08.005 |
0.312 |
|
| 2019 |
Davids MS, Brander DM, Kim HT, Tyekucheva S, Bsat J, Savell A, Hellman JM, Bazemore J, Francoeur K, Alencar A, Shune L, Omaira M, Jacobson CA, Armand P, Ng S, ... ... Brown JR, et al. Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial. The Lancet. Haematology. PMID 31208944 DOI: 10.1016/S2352-3026(19)30104-8 |
0.343 |
|
| 2019 |
Lampson BL, Kim HT, Davids MS, Abramson JS, Freedman AS, Jacobson CA, Armand PA, Joyce RM, Arnason JE, Rassenti LZ, Kipps TJ, Fein J, Fernandes SM, Hanna JR, Fisher DC, ... Brown JR, et al. Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia. Blood Advances. 3: 1167-1174. PMID 30967392 DOI: 10.1182/bloodadvances.2018030221 |
0.335 |
|
| 2019 |
Byrd JC, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Barr PM, Furman RR, Kipps TJ, Thornton P, Moreno C, Montillo M, ... ... Brown JR, et al. Long-term follow-up of the RESONATE™ phase 3 trial of ibrutinib versus ofatumumab. Blood. PMID 30842083 DOI: 10.1182/Blood-2018-08-870238 |
0.306 |
|
| 2018 |
Dang A, De Leo S, Bogdanowicz DR, Yuan DJ, Fernandes SM, Brown JR, Lu HH, Kam LC. Enhanced activation and expansion of T cells using mechanically soft elastomer fibers. Advanced Biosystems. 2. PMID 31008184 DOI: 10.1002/adbi.201700167 |
0.355 |
|
| 2018 |
Davids MS, Kim HT, Nicotra A, Savell A, Francoeur K, Hellman JM, Bazemore J, Miskin HP, Sportelli P, Stampleman L, Maegawa R, Rueter J, Boruchov AM, Arnason JE, Jacobson CA, ... ... Brown JR, et al. Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study. The Lancet. Haematology. PMID 30558987 DOI: 10.1016/S2352-3026(18)30196-0 |
0.387 |
|
| 2018 |
Brown JR. Relapsed CLL: sequencing, combinations, and novel agents. Hematology. American Society of Hematology. Education Program. 2018: 248-255. PMID 30504318 DOI: 10.1182/asheducation-2018.1.248 |
0.338 |
|
| 2018 |
Dong S, Harrington BK, Hu EY, Greene JT, Lehman AM, Tran M, Wasmuth RL, Long M, Muthusamy N, Brown JR, Johnson AJ, Byrd JC. PI3K p110δ inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppression. The Journal of Clinical Investigation. PMID 30457982 DOI: 10.1172/Jci99386 |
0.432 |
|
| 2018 |
Barrientos JC, O'Brien S, Brown JR, Kay NE, Reddy NM, Coutre S, Tam C, Mulligan S, Jaeger U, Devereux S, Pocock C, Robak T, Schuster SJ, Schuh A, Gill D, et al. Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Clinical Lymphoma, Myeloma & Leukemia. PMID 30249389 DOI: 10.1016/J.Clml.2018.08.007 |
0.305 |
|
| 2018 |
Brown JR, Hamadani M, Hayslip J, Janssens A, Wagner-Johnston N, Ottmann O, Arnason J, Tilly H, Millenson M, Offner F, Gabrail NY, Ganguly S, Ailawadh S, Kasar S, Kater AP, et al. Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial. The Lancet. Haematology. PMID 29550382 DOI: 10.1016/S2352-3026(18)30030-9 |
0.354 |
|
| 2018 |
Nørgaard CH, Jakobsen LH, Gentles AJ, Dybkær K, El-Galaly TC, Bødker JS, Schmitz A, Johansen P, Herold T, Spiekermann K, Brown JR, Klitgaard JL, Johnsen HE, Bøgsted M. Subtype assignment of CLL based on B-cell subset associated gene signatures from normal bone marrow - A proof of concept study. Plos One. 13: e0193249. PMID 29513759 DOI: 10.1371/journal.pone.0193249 |
0.313 |
|
| 2018 |
Lampson BL, Brown JR. Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia? Expert Review of Hematology. PMID 29381098 DOI: 10.1080/17474086.2018.1435268 |
0.366 |
|
| 2018 |
Itchaki G, Brown JR. Experience with ibrutinib for first-line use in patients with chronic lymphocytic leukemia. Therapeutic Advances in Hematology. 9: 3-19. PMID 29317997 DOI: 10.1177/2040620717741861 |
0.393 |
|
| 2017 |
Wierda WG, Byrd JC, Abramson JS, Bhat S, Bociek G, Brander D, Brown J, Chanan-Khan A, Coutre SE, Davis RS, Fletcher CD, Hill B, Kahl BS, Kamdar M, Kaplan LD, et al. Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : Jnccn. 15: 1414-1427. PMID 29118233 DOI: 10.6004/Jnccn.2017.0165 |
0.353 |
|
| 2017 |
Lampson BL, Brown JR. PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma. Expert Opinion On Investigational Drugs. PMID 28945111 DOI: 10.1080/13543784.2017.1384815 |
0.433 |
|
| 2017 |
Arnason JE, Brown JR. Targeting B Cell Signaling in Chronic Lymphocytic Leukemia. Current Oncology Reports. 19: 61. PMID 28755313 DOI: 10.1007/s11912-017-0620-7 |
0.326 |
|
| 2017 |
Gordon MJ, Lewis LD, Brown JR, Danilov AV. Bendamustine hydrochloride in patients with B-cell malignancies who have comorbidities - Is there an optimal dose? Expert Review of Hematology. PMID 28664772 DOI: 10.1080/17474086.2017.1350166 |
0.324 |
|
| 2017 |
Aw A, Brown JR. Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies. Drugs & Aging. PMID 28536906 DOI: 10.1007/s40266-017-0468-4 |
0.42 |
|
| 2017 |
Aw A, Brown JR. The potential combination of BCL-2 inhibitors and ibrutinib as frontline therapy in chronic lymphocytic leukemia. Leukemia & Lymphoma. 1-11. PMID 28482721 DOI: 10.1080/10428194.2017.1312387 |
0.408 |
|
| 2017 |
Compagno M, Wang Q, Pighi C, Cheong TC, Meng FL, Poggio T, Yeap LS, Karaca E, Blasco RB, Langellotto F, Ambrogio C, Voena C, Wiestner A, Kasar SN, Brown JR, et al. Phosphatidylinositol 3-kinase δ blockade increases genomic instability in B cells. Nature. PMID 28199309 DOI: 10.1038/Nature21406 |
0.314 |
|
| 2017 |
Zelenetz AD, Barrientos JC, Brown JR, Coiffier B, Delgado J, Egyed M, Ghia P, Illés Á, Jurczak W, Marlton P, Montillo M, Morschhauser F, Pristupa AS, Robak T, Sharman JP, et al. Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Oncology. PMID 28139405 DOI: 10.1016/S1470-2045(16)30671-4 |
0.317 |
|
| 2016 |
Wang L, Brooks AN, Fan J, Wan Y, Gambe R, Li S, Hergert S, Yin S, Freeman SS, Levin JZ, Fan L, Seiler M, Buonamici S, Smith PG, Chau KF, ... ... Brown JR, et al. Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia. Cancer Cell. PMID 27818134 DOI: 10.1016/J.Ccell.2016.10.005 |
0.315 |
|
| 2016 |
Ryan CE, Sahaf B, Logan AC, O'Brien S, Byrd JC, Hillmen P, Brown JR, Dyer MJ, Mato AR, Keating MJ, Jaglowski S, Clow F, Rezvani AR, Styles L, Coutre SE, et al. Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT. Blood. PMID 27802969 DOI: 10.1182/blood-2016-06-715284 |
0.438 |
|
| 2016 |
Itchaki G, Brown JR. The potential of venetoclax (ABT-199) in chronic lymphocytic leukemia. Therapeutic Advances in Hematology. 7: 270-287. PMID 27695617 DOI: 10.1177/2040620716655350 |
0.314 |
|
| 2016 |
Kharfan-Dabaja MA, Kumar A, Hamadani M, Stilgenbauer S, Ghia P, Anasetti C, Dreger P, Montserrat E, Perales MA, Alyea EP, Awan FT, Ayala E, Barrientos JC, Brown JR, Castro J, et al. Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 27660167 DOI: 10.1016/J.Bbmt.2016.09.013 |
0.301 |
|
| 2016 |
Pavlasova G, Borsky M, Seda V, Cerna K, Osickova J, Doubek M, Mayer J, Calogero R, Trbusek M, Pospisilova S, Davids MS, Kipps TJ, Brown JR, Mraz M. Ibrutinib inhibits CD20 up-regulation on CLL B cells mediated by the CXCR4/SDF-1 axis. Blood. PMID 27480113 DOI: 10.1182/blood-2016-04-709519 |
0.323 |
|
| 2016 |
Kurimchak AM, Shelton C, Duncan KE, Johnson KJ, Brown J, O'Brien S, Gabbasov R, Fink LS, Li Y, Lounsbury N, Abou-Gharbia M, Childers WE, Connolly DC, Chernoff J, Peterson JR, et al. Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer. Cell Reports. PMID 27452461 DOI: 10.1016/J.Celrep.2016.06.091 |
0.334 |
|
| 2016 |
Liu X, Wang A, Liang X, Liu J, Zou F, Chen C, Zhao Z, Deng Y, Wu H, Qi Z, Wang B, Wang L, Liu F, Xu Y, Wang W, ... ... Brown JR, et al. Simultaneous inhibition of Vps34 kinase would enhance PI3Kδ inhibitor cytotoxicity in the B-cell malignancies. Oncotarget. PMID 27447747 DOI: 10.18632/Oncotarget.10650 |
0.342 |
|
| 2016 |
Brown JR, Hallek MJ, Pagel JM. Chemoimmunotherapy Versus Targeted Treatment in Chronic Lymphocytic Leukemia: When, How Long, How Much, and in Which Combination? American Society of Clinical Oncology Educational Book / Asco. American Society of Clinical Oncology. Meeting. 35: e387-e398. PMID 27249745 DOI: 10.14694/EDBK_159018 |
0.357 |
|
| 2016 |
Lampson BL, Kasar SN, Matos TR, Morgan EA, Rassenti L, Davids MS, Fisher DC, Freedman AS, Jacobson CA, Armand P, Abramson JS, Arnason JE, Kipps TJ, Fein J, Fernandes S, ... ... Brown JR, et al. Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood. PMID 27247136 DOI: 10.1182/blood-2016-03-707133 |
0.332 |
|
| 2016 |
Thijssen R, Ter Burg J, Garrick B, van Bochove GG, Brown JR, Fernandes SM, Rodríguez MS, Michot JM, Hallek M, Eichhorst B, Reinhardt HC, Bendell J, Derks IA, van Kampen RJ, Hege K, et al. Dual TORK/DNA-PK inhibition blocks critical signalling pathways in chronic lymphocytic leukemia. Blood. PMID 27235137 DOI: 10.1182/blood-2016-02-700328 |
0.452 |
|
| 2016 |
Burger JA, Landau DA, Taylor-Weiner A, Bozic I, Zhang H, Sarosiek K, Wang L, Stewart C, Fan J, Hoellenriegel J, Sivina M, Dubuc AM, Fraser C, Han Y, Li S, ... ... Brown JR, et al. Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. Nature Communications. 7: 11589. PMID 27199251 DOI: 10.1038/Ncomms11589 |
0.412 |
|
| 2016 |
Brown JR, Harb WA, Hill BT, Gabrilove J, Sharman JP, Schreeder MT, Barr PM, Foran JM, Miller TP, Burger JA, Kelly KR, Mahadevan D, Ma S, Li Y, Pierce DW, et al. Phase 1 study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed or refractory chronic lymphocytic leukemia. Haematologica. PMID 27151992 DOI: 10.3324/Haematol.2015.140806 |
0.348 |
|
| 2016 |
Yang G, Buhrlage S, Tan L, Liu X, Chen J, Xu L, Tsakmaklis N, Chen JG, Patterson CJ, Brown JR, Castillo JJ, Zhang W, Zhang X, Liu S, Cohen P, et al. HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib. Blood. PMID 27143257 DOI: 10.1182/Blood-2016-01-695098 |
0.319 |
|
| 2016 |
Liu X, Wang A, Liang X, Chen C, Liu J, Zhao Z, Wu H, Deng Y, Wang L, Wang B, Wu J, Liu F, Fernandes SM, Adamia S, Stone RM, ... ... Brown JR, et al. Characterization of selective and potent PI3Kδ inhibitor (PI3KDIN- 015) for B-Cell malignances. Oncotarget. PMID 27081697 DOI: 10.18632/Oncotarget.8702 |
0.342 |
|
| 2016 |
Anderson MA, Deng J, Seymour JF, Tam C, Kim SY, Fein J, Yu L, Brown JR, Westerman D, Si EG, Majewski IJ, Segal D, Heitner Enschede SL, Huang DC, Davids MS, et al. The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53 independent mechanism. Blood. PMID 27069256 DOI: 10.1182/Blood-2016-01-688796 |
0.369 |
|
| 2016 |
Brown JR. The PI3K pathway: clinical inhibition in chronic lymphocytic leukemia. Seminars in Oncology. 43: 260-4. PMID 27040704 DOI: 10.1053/j.seminoncol.2016.02.004 |
0.404 |
|
| 2015 |
Flowers CR, Brown JR, Rosenthal H, Stock W, Katzen HI, Cohen JB, Sinha R, Lakhanpal S, Leis JF, Waller EK, Jaye DL. A Phase 2 Trial of Fludarabine Combined With Subcutaneous Alemtuzumab for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia. Clinical Lymphoma, Myeloma & Leukemia. PMID 26385641 DOI: 10.1016/j.clml.2015.07.640 |
0.321 |
|
| 2015 |
Brown JR, Davids MS, Rodon J, Abrisqueta P, Kasar SN, Lager J, Jiang J, Egile C, Awan FT. Phase I Trial of the Pan-PI3K Inhibitor Pilaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory Lymphoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 3160-9. PMID 25840972 DOI: 10.1158/1078-0432.CCR-14-3262 |
0.322 |
|
| 2015 |
Brown JR, Barrientos JC, Barr PM, Flinn IW, Burger JA, Tran A, Clow F, James DF, Graef T, Friedberg JW, Rai K, O'Brien S. The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia. Blood. 125: 2915-22. PMID 25755291 DOI: 10.1182/blood-2014-09-585869 |
0.334 |
|
| 2015 |
Arnason JE, Brown JR. Targeted therapy for chronic lymphocytic leukemia: current status and future directions. Drugs. 75: 143-55. PMID 25619739 DOI: 10.1007/s40265-014-0338-x |
0.343 |
|
| 2014 |
Arnason JE, Brown JR. B cell receptor pathway in chronic lymphocytic leukemia: specific role of CC-292. Immunotargets and Therapy. 3: 29-38. PMID 27471698 DOI: 10.2147/ITT.S37419 |
0.368 |
|
| 2014 |
Shindiapina P, Brown JR, Danilov AV. A new hope: novel therapeutic approaches to treatment of chronic lymphocytic leukaemia with defects in TP53. British Journal of Haematology. 167: 149-61. PMID 25040077 DOI: 10.1111/bjh.13042 |
0.369 |
|
| 2014 |
Davids MS, Brown JR. Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase. Future Oncology (London, England). 10: 957-67. PMID 24941982 DOI: 10.2217/fon.14.51 |
0.331 |
|
| 2014 |
Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Devereux S, Barr PM, Furman RR, Kipps TJ, Cymbalista F, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. The New England Journal of Medicine. 371: 213-23. PMID 24881631 DOI: 10.1056/Nejmoa1400376 |
0.312 |
|
| 2014 |
Brown JR, Porter DL, O'Brien SM. Novel treatments for chronic lymphocytic leukemia and moving forward. American Society of Clinical Oncology Educational Book / Asco. American Society of Clinical Oncology. Meeting. e317-25. PMID 24857119 DOI: 10.14694/EdBook_AM.2014.34.e317 |
0.422 |
|
| 2014 |
Kahl BS, Spurgeon SE, Furman RR, Flinn IW, Coutre SE, Brown JR, Benson DM, Byrd JC, Peterman S, Cho Y, Yu A, Godfrey WR, Wagner-Johnston ND. A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). Blood. 123: 3398-405. PMID 24615778 DOI: 10.1182/blood-2013-11-537555 |
0.321 |
|
| 2014 |
Brown JR, Byrd JC, Coutre SE, Benson DM, Flinn IW, Wagner-Johnston ND, Spurgeon SE, Kahl BS, Bello C, Webb HK, Johnson DM, Peterman S, Li D, Jahn TM, Lannutti BJ, et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia. Blood. 123: 3390-7. PMID 24615777 DOI: 10.1182/blood-2013-11-535047 |
0.41 |
|
| 2014 |
Flinn IW, Kahl BS, Leonard JP, Furman RR, Brown JR, Byrd JC, Wagner-Johnston ND, Coutre SE, Benson DM, Peterman S, Cho Y, Webb HK, Johnson DM, Yu AS, Ulrich RG, et al. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood. 123: 3406-13. PMID 24615776 DOI: 10.1182/blood-2013-11-538546 |
0.318 |
|
| 2014 |
Wu H, Wang W, Liu F, Weisberg EL, Tian B, Chen Y, Li B, Wang A, Wang B, Zhao Z, McMillin DW, Hu C, Li H, Wang J, Liang Y, ... ... Brown JR, et al. Discovery of a potent, covalent BTK inhibitor for B-cell lymphoma. Acs Chemical Biology. 9: 1086-91. PMID 24556163 DOI: 10.1021/Cb4008524 |
0.306 |
|
| 2014 |
Brown JR. Ibrutinib in chronic lymphocytic leukemia and B cell malignancies Leukemia and Lymphoma. 55: 263-269. PMID 23656200 DOI: 10.3109/10428194.2013.803226 |
0.343 |
|
| 2013 |
Davids MS, Letai A, Brown JR. Overcoming stroma-mediated treatment resistance in chronic lymphocytic leukemia through BCL-2 inhibition. Leukemia & Lymphoma. 54: 1823-1825. PMID 23614795 DOI: 10.3109/10428194.2013.796051 |
0.374 |
|
| 2013 |
Davids MS, Brown JR. Phosphoinositide 3'-kinase inhibition in chronic lymphocytic leukemia. Hematology/Oncology Clinics of North America. 27: 329-39. PMID 23561476 DOI: 10.1016/j.hoc.2012.12.002 |
0.342 |
|
| 2013 |
Brown JR. Ibrutinib (PCI-32765), the first BTK (Bruton's tyrosine kinase) inhibitor in clinical trials. Current Hematologic Malignancy Reports. 8: 1-6. PMID 23296407 DOI: 10.1007/s11899-012-0147-9 |
0.397 |
|
| 2013 |
Davids MS, Brown JR. Targeting the B cell receptor pathway in chronic lymphocytic leukemia. Leukemia & Lymphoma. 53: 2362-70. PMID 22616724 DOI: 10.3109/10428194.2012.695781 |
0.334 |
|
| 2012 |
Shalek AK, Gaublomme JT, Wang L, Yosef N, Chevrier N, Andersen MS, Robinson JT, Pochet N, Neuberg D, Gertner RS, Amit I, Brown JR, Hacohen N, Regev A, Wu CJ, et al. Nanowire-mediated delivery enables functional interrogation of primary immune cells: application to the analysis of chronic lymphocytic leukemia. Nano Letters. 12: 6498-504. PMID 23190424 DOI: 10.1021/Nl3042917 |
0.33 |
|
| 2012 |
Davids MS, Deng J, Wiestner A, Lannutti BJ, Wang L, Wu CJ, Wilson WH, Brown JR, Letai A. Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia. Blood. 120: 3501-9. PMID 22955911 DOI: 10.1182/Blood-2012-02-414060 |
0.398 |
|
| 2012 |
Roberts AW, Seymour JF, Brown JR, Wierda WG, Kipps TJ, Khaw SL, Carney DA, He SZ, Huang DC, Xiong H, Cui Y, Busman TA, McKeegan EM, Krivoshik AP, Enschede SH, et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 488-96. PMID 22184378 DOI: 10.1200/JCO.2011.34.7898 |
0.312 |
|
| 2011 |
Brown JR. The treatment of relapsed refractory chronic lymphocytic leukemia Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 2011: 110-118. PMID 22160021 DOI: 10.1182/asheducation-2011.1.110 |
0.362 |
|
| 2011 |
Wang L, Lawrence MS, Wan Y, Stojanov P, Sougnez C, Stevenson K, Werner L, Sivachenko A, DeLuca DS, Zhang L, Zhang W, Vartanov AR, Fernandes SM, Goldstein NR, Folco EG, ... ... Brown JR, et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. The New England Journal of Medicine. 365: 2497-506. PMID 22150006 DOI: 10.1056/Nejmoa1109016 |
0.307 |
|
| 2011 |
Ge X, Wu L, Hu W, Fernandes S, Wang C, Li X, Brown JR, Qin X. rILYd4, a human CD59 inhibitor, enhances complement-dependent cytotoxicity of ofatumumab against rituximab-resistant B-cell lymphoma cells and chronic lymphocytic leukemia. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 6702-11. PMID 21918174 DOI: 10.1158/1078-0432.CCR-11-0647 |
0.34 |
|
| 2011 |
Amrein PC, Attar EC, Takvorian T, Hochberg EP, Ballen KK, Leahy KM, Fisher DC, LaCasce AS, Jacobsen ED, Armand P, Hasserjian RP, Werner L, Neuberg D, Brown JR. Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia Clinical Cancer Research. 17: 2977-2986. PMID 21402714 DOI: 10.1158/1078-0432.CCR-10-2879 |
0.329 |
|
| 2011 |
Abou-Nassar K, Brown JR. Novel agents for the treatment of chronic lymphocytic leukemia. Clinical Advances in Hematology & Oncology : H&O. 8: 886-95. PMID 21326166 |
0.309 |
|
| 2011 |
Hu W, Ge X, You T, Xu T, Zhang J, Wu G, Peng Z, Chorev M, Aktas BH, Halperin JA, Brown JR, Qin X. Human CD59 inhibitor sensitizes rituximab-resistant lymphoma cells to complement-mediated cytolysis. Cancer Research. 71: 2298-307. PMID 21252115 DOI: 10.1158/0008-5472.CAN-10-3016 |
0.395 |
|
| 2011 |
Wierda WG, Chiorazzi N, Dearden C, Brown JR, Montserrat E, Shpall E, Stilgenbauer S, Muneer S, Grever M. Chronic lymphocytic leukemia: new concepts for future therapy. Clinical Lymphoma, Myeloma & Leukemia. 10: 369-78. PMID 21030350 DOI: 10.3816/CLML.2010.n.070 |
0.329 |
|
| 2008 |
Rassenti LZ, Jain S, Keating MJ, Wierda WG, Grever MR, Byrd JC, Kay NE, Brown JR, Gribben JG, Neuberg DS, He F, Greaves AW, Rai KR, Kipps TJ. Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood. 112: 1923-30. PMID 18577710 DOI: 10.1182/Blood-2007-05-092882 |
0.344 |
|
| 2004 |
Brown JR, Weng AP, Freedman AS. Hodgkin disease associated with T-cell non-Hodgkin lymphomas: case reports and review of the literature. American Journal of Clinical Pathology. 121: 701-8. PMID 15151210 DOI: 10.1309/W1GW-43HT-793U-F86R |
0.322 |
|
| Show low-probability matches. |